Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy
Abstract Objective To determine the efficacy and safety of combined low‐dose rituximab with conventional therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment. Methods Total 73 patients with CIDP were enrolled for the retrospective cohort study, and divided into conv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.52270 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592679042547712 |
|---|---|
| author | Ying Du Qi Yan Chuan Li Wenping Zhu Chao Zhao Yunfeng Hao Lin Li Dan Yao Xuan Zhou Ying Li Yuting Dang Rong Zhang Lin Han Yuanyuan Wang Tao Hou Juan Li Hailin Li Panpan Jiang Pei Wang Fenying Chen Tingge Zhu Juntong Liu Shuyu Liu Lan Gao Yingjun Zhao Wei Zhang |
| author_facet | Ying Du Qi Yan Chuan Li Wenping Zhu Chao Zhao Yunfeng Hao Lin Li Dan Yao Xuan Zhou Ying Li Yuting Dang Rong Zhang Lin Han Yuanyuan Wang Tao Hou Juan Li Hailin Li Panpan Jiang Pei Wang Fenying Chen Tingge Zhu Juntong Liu Shuyu Liu Lan Gao Yingjun Zhao Wei Zhang |
| author_sort | Ying Du |
| collection | DOAJ |
| description | Abstract Objective To determine the efficacy and safety of combined low‐dose rituximab with conventional therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment. Methods Total 73 patients with CIDP were enrolled for the retrospective cohort study, and divided into conventional first‐line therapy cohort (n = 40) and combined low‐dose rituximab (100 mg per infusion) cohort (n = 33). The outcome measures include scores of I‐RODS, mRS, INCAT, ONLS, TSS, and COMPASS 31 scale at baseline and regular four visits (4, 16, 28, and 52 weeks), as well as proportion of favorable response and outcome, corticosteroids dosage, and deterioration occurrence during follow‐up. Results Compared to conventional therapy cohort, combined rituximab cohort presented better improvements and higher proportion of favorable response in scales assessments at each visit, as well as significantly reduced corticosteroids dosage and deterioration occurrence during the follow‐up. Analyses of subgroups showed better improvements in both typical CIDP and CIDP variants in combined rituximab cohort than those in conventional therapy cohort, but had no differences between each other. Early initiating combined rituximab regimen (<10 weeks) showed better improvements than delayed initiation (≥10 weeks) at the first three visits within 28 weeks, while had no difference in favorable prognoses at the last visit of 52 weeks after once reinfusion. No rituximab correlated serious adverse events were reported in our patients. Interpretation Our simplified regimen of combined low‐dose rituximab has been firstly demonstrated for the better efficacy and safety than conventional therapy in CIDP treatment. |
| format | Article |
| id | doaj-art-e19bd4958f1941828887b8a60cd782c3 |
| institution | Kabale University |
| issn | 2328-9503 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj-art-e19bd4958f1941828887b8a60cd782c32025-01-21T05:41:42ZengWileyAnnals of Clinical and Translational Neurology2328-95032025-01-0112118019110.1002/acn3.52270Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathyYing Du0Qi Yan1Chuan Li2Wenping Zhu3Chao Zhao4Yunfeng Hao5Lin Li6Dan Yao7Xuan Zhou8Ying Li9Yuting Dang10Rong Zhang11Lin Han12Yuanyuan Wang13Tao Hou14Juan Li15Hailin Li16Panpan Jiang17Pei Wang18Fenying Chen19Tingge Zhu20Juntong Liu21Shuyu Liu22Lan Gao23Yingjun Zhao24Wei Zhang25Department of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Internal Medicine Qianxian Traditional Chinese Medicine Hospital Xianyang 713300 Shaanxi ChinaDepartment of Neurology Fuping County Hospital Weinan 711700 Shaanxi ChinaDepartment of Neurology Lantian Country People's Hospital Xi'an 710500 Shaanxi ChinaDepartment of Neurology Pingli County Hospital Ankang 725500 Shaanxi ChinaDepartment of Neurology The Second Hospital of Weinan Weinan 711700 Shaanxi ChinaDepartment of Internal Medicine Baishui County Hospital Weinan 715600 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaDepartment of Neurology and Department of Neuroscience, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, School of Medicine Xiamen University Xiamen 361005 Fujian ChinaDepartment of Neurology, Tangdu Hospital Fourth Military Medical University Xi'an 710038 Shaanxi ChinaAbstract Objective To determine the efficacy and safety of combined low‐dose rituximab with conventional therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment. Methods Total 73 patients with CIDP were enrolled for the retrospective cohort study, and divided into conventional first‐line therapy cohort (n = 40) and combined low‐dose rituximab (100 mg per infusion) cohort (n = 33). The outcome measures include scores of I‐RODS, mRS, INCAT, ONLS, TSS, and COMPASS 31 scale at baseline and regular four visits (4, 16, 28, and 52 weeks), as well as proportion of favorable response and outcome, corticosteroids dosage, and deterioration occurrence during follow‐up. Results Compared to conventional therapy cohort, combined rituximab cohort presented better improvements and higher proportion of favorable response in scales assessments at each visit, as well as significantly reduced corticosteroids dosage and deterioration occurrence during the follow‐up. Analyses of subgroups showed better improvements in both typical CIDP and CIDP variants in combined rituximab cohort than those in conventional therapy cohort, but had no differences between each other. Early initiating combined rituximab regimen (<10 weeks) showed better improvements than delayed initiation (≥10 weeks) at the first three visits within 28 weeks, while had no difference in favorable prognoses at the last visit of 52 weeks after once reinfusion. No rituximab correlated serious adverse events were reported in our patients. Interpretation Our simplified regimen of combined low‐dose rituximab has been firstly demonstrated for the better efficacy and safety than conventional therapy in CIDP treatment.https://doi.org/10.1002/acn3.52270 |
| spellingShingle | Ying Du Qi Yan Chuan Li Wenping Zhu Chao Zhao Yunfeng Hao Lin Li Dan Yao Xuan Zhou Ying Li Yuting Dang Rong Zhang Lin Han Yuanyuan Wang Tao Hou Juan Li Hailin Li Panpan Jiang Pei Wang Fenying Chen Tingge Zhu Juntong Liu Shuyu Liu Lan Gao Yingjun Zhao Wei Zhang Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy Annals of Clinical and Translational Neurology |
| title | Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| title_full | Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| title_fullStr | Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| title_full_unstemmed | Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| title_short | Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| title_sort | efficacy and safety of combined low dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy |
| url | https://doi.org/10.1002/acn3.52270 |
| work_keys_str_mv | AT yingdu efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT qiyan efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT chuanli efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT wenpingzhu efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT chaozhao efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT yunfenghao efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT linli efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT danyao efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT xuanzhou efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT yingli efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT yutingdang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT rongzhang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT linhan efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT yuanyuanwang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT taohou efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT juanli efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT hailinli efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT panpanjiang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT peiwang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT fenyingchen efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT tinggezhu efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT juntongliu efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT shuyuliu efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT langao efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT yingjunzhao efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy AT weizhang efficacyandsafetyofcombinedlowdoserituximabregimenforchronicinflammatorydemyelinatingpolyradiculoneuropathy |